产品名称PE/Cy5®偶联试剂盒 - Lightning-Link®
PE/Cy5® Conjugation Kit / PE/Cy5® Labeing Kit ab102871 uses a simple and quick process for PE/Cy5 labeling / conjugation of antibodies. It can also be used to conjugate other proteins or peptides. Learn about our antibody labeling kits and their advantages.
To conjugate an antibody to PE/Cy5® using this kit:
- add modifier to antibody and incubate for 3 hrs
- add quencher and incubate for 30 mins
The PE/Cy5 conjugated antibody can be used immediately in WB, ELISA, IHC etc. No further purification is required and 100% of the antibody is recovered for use.
Learn about buffer compatibility below; for incompatible buffers and low antibody concentrations, use our rapid antibody purification and concentration kits. Use the FAQ to learn more about the technology, or about conjugating other proteins and peptides to PE/Cy5®.
Custom size conjugation kits up to 100 mg are available on demand. Please contact us to discuss your requirements.
This product is manufactured by Expedeon, an Abcam company, and was previously called Lightning-Link® R-PE/Cy5 Labeling Kit. 760-0005 is the same as the 60 µg size. 760-0010 is the same as the 3 x 60 ug size. 760-0030 is the same as the 3 x 10 ug size. 760-0015 is the same as the 600 µg size.
Amount and volume of antibody for conjugation to PE/Cy5®.
Kit size Recommended
amount of antibody
3 x 10 µg 3 x 10 µg 3 x 10 µL 60 µg 1 x 60 µg 1 x 60 µL 3 x 60 µg 3 x 60 µg 3 x 60 µL 600 µg 1 x 600 µg 1 x 600 µL
1Ideal antibody concentration is 1mg/ml. 0.5 - 1 mg/ml can be used if the maximum antibody volume is not exceeded. Antibodies > 1 mg/ml or < 0.5 mg/ml should be diluted /concentrated.
The selling size of this product has been changed – it is now based on the amount of antibody that can be conjugated with the kit, not the amount of PE mix provided. The amount of antibody advised that can be used with the kit has also been updated to reflect what will give the best conjugation results. The quantity and formulation of reagents provided have not changed, if you have been previously using the kit successfully with a different amount of antibody, there is no need to change the way that you are using the kit.
Buffer Requirements for Conjugation
Buffer should be pH 6.5-8.5.
Compatible buffer constituents
If a concentration is shown, then the constituent should be no more than the concentration shown. If several constituents are close to the limit of acceptable concentration, then this can inhibit conjugation.
50mM / 0.6% Tris1 0.1% BSA 50% glycerol 0.1% sodium azide PBS Potassium phosphate Sodium chloride HEPES Sucrose Sodium citrate EDTA Trehalose
1 Tris buffered saline is almost always ≤ 50 mM / 0.6%
Incompatible buffer constituents
Thiomerosal Proclin Glycine Arginine Glutathione DTT
Only purified antibodies are suitable for use, ie. where other proteins, peptides, or amino acids are not present: antibodies in ascites fluid, serum or hybridoma culture media are incompatible.
存放说明Store at -20°C. Please refer to protocols.
组件 600 µg 60 µg 3 x 10 µg 3 x 60 µg ab274106 - Modifier reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl ab274144 - PE/Cy5 mix 1 x 600µg 1 x 60µg 3 x 10µg 3 x 60µg ab274133 - Quencher reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl
Bardhan, Kankana, et al used PE/Cy5® Conjugation Kit - Lightning-Link® (ab102893) as part of examining PD-1pY248+ (pPD-1) expression in human T cells. They used the kit to conjugate PE/Cy5® to Anti-PD-1pY248 antibody for use in flow cytometry.
pPD-1 is predominantly expressed in CD8+ TCM cells. CCR7 and CD45RO markers were used to identify central memory (TCM) and effector memory (TEM) T cells. After gating on CD45RO expression, TCM (CD45RO+CCR7+) and TEM (CD45RO+CCR7) CD4+ and CD8+ T cells were identified by assessing expression of CCR7. In TCM and TEM populations, expression of PD-1 was determined and, subsequently, expression of pPD-1 (pPD-1-Y248) was assessed in the PD-1+ population within each subset. Results are representative of six separate experiments.
Taichman, Russell S., et al used PE/Cy5® Conjugation Kit - Lightning-Link® (ab102893) as part of examining Axl and Tyro3 expression during experimental prostate cancer (PCa) progression. They used the kit to conjugate PE/Cy5® to antibodies for use in flow cytometry.
Anti-Axl, anti-Tyro3 and anti-Ki67 antibodies were conjugated to the fluorophores APC-Cy7, PE-Cy5, and Atto390 using our Lightning-Link® Conjugation kits. (A) Experimental model. Human PCa cell lines (PC3Luc, DU145Luc) were implanted s.c. into male SCID mice as a model of a primary (1°) tumor development, and removed after 1 month. At monthly intervals thereafter human PCa cells were identified by anti-HLA staining; proliferative status (Ki67 staining) and Axl or Tyro3 levels were evaluated by FACS. (B) Percent expression of Ki67 by lineage depleted (Lin-) marrow cells or by primary tumor cells at 1 month. (C-D) Percent expression of Axl or Tyro3 by primary tumor cells established with (C) DU145 or (D) PC3 cells or by DTCs recovered from marrow over time.
White, Matthew J., et al used PE/Cy5® Conjugation Kit - Lightning-Link® (ab102893) as part of examining Interleukin‐12 receptor β2 (IL‐12Rβ2) expression relatively to CD57 expression in Peripheral blood mononuclear cells (PBMC). They used the kit to conjugate PE/Cy5® to anti-IL‐12Rβ2 monoclonal antibody for use in flow cytometry.
PBMC were analysed ex vivo for IL‐12Rβ2 expression. (a) Representative flow cytometry plots for IL‐12Rβ2. Frequency (b) and mean fluorescence intensity (MFI) (c) of IL‐12Rβ2 expression were assessed by subset. Each data point represents one donor, n = 19. Lines indicate median values. CD56dim subsets were analysed for linear trend with a repeated measures analysis of variance. ****P ≤ 0.0001.
Nielsen, Carolyn M., et al used PE/Cy5® Conjugation Kit - Lightning-Link® (ab102893) to conjugate PE/Cy5® to anti-IL-12Rβ2 antibody for use in flow cytometry.
NK cells were analyzed for surface expression of 12Rβ2 using an mIgG1 PECy5-conjugated isotype control to set the gate.
Kim, Nayoung, et al used PE/Cy5® Conjugation Kit - Lightning-Link® (ab102893) as part of examining apoptosis in HIV-1-infected CD4+ primary T cells. They used the kit to conjugate PE/Cy5® to anti-FOXO3a antibody for use in confocal microscopy.
Jurkat T cells expressing tTA alone, TatSF2+tTA, or TatSF2G48-R57A +tTA were stained with antibodies against PPP2R1B (first and forth columns of panels, green), pFOXO3a (second column, red), and FOXO3a (forth column, red).
Olling, Alexandra, et al used PE/Cy5® Conjugation Kit - Lightning-Link® (ab102893) as part of examining the role of toxins in the pathogenicity of Clostridium difficile. They used the kit to conjugate PE/Cy5® to for use in flow cytometry.Binding of fluorescent labeled TcdA-PE/Cy5 and TcdA11874-Atto488 to HT29 and CHO-C6 cells was investigated by FACS analysis. Right shift of the black curve illustrates toxin binding which was detected through fluorescence emission at 667 nm for TcdA and at 523 nm for TcdA1-1874, respectively. Due to different ratio of fluorophor and toxin, fluorescence intensity of TcdA-PE/Cy5 cannot directly be compared with TcdA1-1874-Atto488.
This illustration demonstrates a general procedure and will slightly vary dependent on the conjugate used.
ab102893 被引用在 9 文献中.
- Henrik Heiland D et al. Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. Nat Commun 10:2541 (2019). PubMed: 31186414
- He S et al. Clonal anergy of CD117+chB6+ B cell progenitors induced by avian leukosis virus subgroup J is associated with immunological tolerance. Retrovirology 16:1 (2019). PubMed: 30602379
- Sun C et al. Central role of IP3R2-mediated Ca2+ oscillation in self-renewal of liver cancer stem cells elucidated by high-signal ER sensor. Cell Death Dis 10:396 (2019). PubMed: 31113961
- Nielsen CM et al. Impaired NK Cell Responses to Pertussis and H1N1 Influenza Vaccine Antigens in Human Cytomegalovirus-Infected Individuals. J Immunol 194:4657-67 (2015). PubMed: 25855356
- White MJ et al. Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens. Immunology 142:140-50 (2014). PubMed: 24843874
- Kakhlon O et al. Polyglucosan neurotoxicity caused by glycogen branching enzyme deficiency can be reversed by inhibition of glycogen synthase. J Neurochem 127:101-13 (2013). PubMed: 23607684
- Taichman RS et al. GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One 8:e61873 (2013). PubMed: 23637920
- Olling A et al. The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin A. PLoS One 6:e17623 (2011). PubMed: 21445253
- Ott S et al. Preparation of epoxy-based macroporous monolithic columns for the fast and efficient immunofiltration of Staphylococcus aureus. J Sep Sci 34:2181-92 (2011). PubMed: 21735547